Board Vitals - Pharmacist

NOVEMBER 15, 2023

The PRITE covers a broad range of topics within the field of psychiatry. Administered annually, it covers a wide array of topics to ensure a well-rounded evaluation of a resident’s understanding of psychiatry. Clinical Neurosciences (69 Items) Neurodevelopment Neuroanatomy Neurophysiology Genetics B. What is the PRITE ?

98

98

Pharmaceutical Technology

JULY 19, 2022

as a topical treatment of nonsegmental vitiligo in adults and paediatric patients aged 12 years and above. Opzelura is a topical formulation of a Janus kinase (JAK) inhibitor. In non-segmental vitiligo patients, it is indicated for continuous topical use twice a day to affected regions of up to 10% body surface area.

Labelling 116

Labelling 116

PharmaState Academy

MAY 2, 2023

Pharmaceutical Sciences Conference 2023: Scheduled to be held on December 4-6, 2023, this conference brings together industry stalwarts, academicians, and researchers to discuss the latest trends, advancements, and challenges in the field of pharmacology, drug discovery, and clinical trials.

98

98

RX Note

JULY 15, 2023

Clinical features of atopic dermatitis include Skin dryness Erythema Oozing and crusting Lichenification Affected individuals often have a family history of asthma , hay fever and/or type 1 food allergy (anaphylactoid reactions). To avoid rebound flare, topical therapy should be resumed while tapering systemic glucocorticoids.

52

52

Express Pharma

JULY 29, 2023

In this video: Sourabh Sobti, Business Development Lead, CEPI Topic: Investments in vaccine delivery Key Highlights: 1) Create vaccine libraries against representative pathogens from virus families with greatest pandemic potential 2) Establish global clinical trials and laboratory networks with pre-established processes and protocols to enable rapid (..)

Vaccines 52

Vaccines 52

European Pharmaceutical Review

MAY 24, 2023

The gene therapy is a topical gel that restores functional copies of the COL7A1 gene to provide wound healing and sustained functional COL7 protein expression with redosing. The US Food and Drug Administration (FDA) has approved the first-ever redosable gene therapy for the rare skin disease dystrophic epidermolysis bullosa (DEB).

101

101

Board Vitals - Pharmacist

FEBRUARY 9, 2024

By taking the time to study some often overlooked topics, you will be ready to do your best come test day. What topics are on the Radiology Core Exam? Sign up for a free trial today to face your exam with confidence. The post 5 of the Most Overlooked Topics on the Radiology Core Exam appeared first on BoardVitals Blog.

52

52

Pharmaceutical Business Review

JANUARY 7, 2024

B244, which is presently being readied for international Phase III clinical trials, is a therapeutic treatment aimed at inflammatory indications such as atopic dermatitis, addressing both appearance and pruritus (itch). Maruho will conduct the Japanese portion of the Phase III trials.

59

59

Express Pharma

JANUARY 11, 2024

GlobalData’s latest report, “Gout Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032,” reveals that there are nine therapies in the late-stage pipeline, most of which are urate-lowering therapies (ULTs) entering the US and Japan markets from 2025 onwards. per cent from $4.6

Biosimilars 85

Biosimilars Compounding 85

Pharmaceutical Technology

DECEMBER 27, 2022

Along the way, mergers and acquisitions continued to happen, new drugs and devices got approved, and innovations in the clinical trial industry were introduced. Drug pricing was a hot-button topic, and William Newton found that while e-commerce chains could cut insulin prices , any major change won’t happen overnight.

Vaccines 122

Vaccines Drug Development Drug Pricing 122

Pharmaceutical Technology

MAY 19, 2023

Myeloid Therapeutics has raised $73m to support the continued clinical development of its lead cell therapy programme, MT-101, in Phase I/II trials for T cell lymphoma. The financing will help to fast-track the development of other in vivo programming candidates into clinical trials.

Labelling 98

Labelling 98

RX Note

JULY 16, 2023

Although topical corticosteroids are frequently used in clinical practice , there is little evidence that they are beneficial in reducing the symptoms and healing time of sunburn. Apply and re-apply sunscreen with a SPF of 50+.

Mayo Clinic 52

Mayo Clinic 52

pharmaphorum

JANUARY 19, 2021

A survey by rare disease patient network Raremark found that 86% of the community members asked were interested in taking part in clinical trials. CEO Jeremy Edwards looks at how decentralised trial models can solve some of the challenges for clinical trial recruitment in rare disease.

Adverse Reactions 133

Adverse Reactions Communication Hospitals Compounding 133

pharmaphorum

NOVEMBER 11, 2022

The lack of diversity in clinical trials has been a topic of debate for decades, but was thrust into the spotlight as the impact of the pandemic on poorer, less educated and ethnically diverse populations became even more apparent. Both groups were poorly represented however in oncology trials. for Hispanics.

97

97

Pharmaceutical Technology

OCTOBER 18, 2022

The portfolio of the company comprises three clinical-stage product candidates, namely OCS-01, OCS-02 and OCS-05. OCS-02 is a topical anti-TNF alpha monoclonal antibody fragment, while OCS-05 is an activator of serum-glucocorticoid kinase 2. “We

Diabetes 59

Diabetes 59

Pharma Leaders

MAY 3, 2023

The FDA has placed a partial clinical hold on Sun Pharma’s IND application for Deuruxolitinib (CTP-543), which was being studied in patients with alopecia areata, an autoimmune disease that includes hair loss. Related Topics

Labelling 52

Labelling 52

Board Vitals - Pharmacist

DECEMBER 8, 2023

We’ve curated a list of the top 10 psychiatry books covering diverse topics to ensure readiness for the ABPN Psychiatry boards. Stahl: Renowned for its comprehensive exploration of psychopharmacology, this guide provides in-depth coverage of mechanisms of action, clinical applications, and side effects of psychotropic medications. .

Compounding 52

Compounding Communication Hospitals 52

Pharma Leaders

APRIL 25, 2023

117Lu-PNT2002 is currently under a phase 3 clinical trial setting, with enrollment complete and top-line data expected in the second half of this year. Related Topics The FDA’s Fast Track process facilitates the development and expedites the review of drugs to treat serious conditions and fill unmet medical needs.

52

52

Pharmaceutical Business Review

MAY 1, 2023

The next generation topical phosphodiesterase-4 (PDE4) inhibitor Zoryve is also indicated to treat psoriasis in the intertriginous areas. This approval marks the first topical PDE4 inhibitor to receive approval outside of the US. “We

Adverse Reactions 52

Adverse Reactions Immunity Immunization 52

Pharmaceutical Business Review

MARCH 5, 2024

In two Phase III clinical trials, the ophthalmic suspension demonstrated quick and lasting clearance of inflammation and pain relief that was statistically and clinically superior to a matching placebo.

59

59

LifeProNow

MARCH 28, 2023

The approval was based on results from the Phase 3 POETYK PSO-1 and POETYK PSO-2 clinical trials, which demonstrated superior efficacy of once-daily Sotyktu compared to placebo and twice-daily Otezla ® (apremilast) at both 16 and 24 weeks, with responses maintained through 52 weeks.

Adverse Reactions 130

Adverse Reactions Immunity Immunization Labelling 130

pharmaphorum

DECEMBER 1, 2021

The vaccine has just started clinical testing, but is designed to control the growth of C acnes on the skin and prevent it from damaging the cellular lining of pores, which can lead to scarring in severe acne cases. Origimm’s expertise in the skin microbiome and antigen discovery will be central to that effort, it added.

Vaccines 105

Vaccines 105

PharmaShots

JANUARY 23, 2023

Until recently, there were very few topical options available for treating plaque psoriasis long-term. Typically, some patients start with topical steroids; however, these can be challenging, as many are limited by where they can be applied on the body and for how long and how often they can be used. of VTAMA cream?

Labelling 40

Labelling Immunity Immunization 40

pharmaphorum

OCTOBER 26, 2022

Topicals — creams, ointments, foams, and lotions applied directly to the affected areas of the skin — don’t get nearly as much TV time as their systemic biologic counterparts, the self-injectables with catchy theme songs, where the smiley and sleeveless walk confidently down the street and/or swim. Both are once-a-day treatments.

Immunity 98

Immunity Immunization Adverse Reactions 98

Pharmaceutical Technology

AUGUST 25, 2022

The approval is based on comprehensive data from the clinical development programme of Roctavian, including two-year findings from the international Phase III GENEr8-1 clinical trial. Topic sponsors are not involved in the creation of editorial content.

105

105

European Pharmaceutical Review

MARCH 28, 2023

Data that supported the approval EC’s approval was based on results from Bristol Myers Squibb’s Phase III POETYK PSO-1 and POETYK PSO-2 clinical trials. The POETYK PSO-1 trial enrolled 666 patients. Current therapies include topicals, orals and biologics. POETYK PSO-2 evaluated 1,020 patients.

Dosage 95

Dosage Immunity Immunization 95

pharmaphorum

FEBRUARY 22, 2022

A virtual menopause clinic service developed by Bia Care is starting a randomised clinical trial within the NHS that will not only test how well it performs, but also attempt to tackle inequalities in women’s health. “This randomised control trial gives a voice to this topic, that cannot be ignored.”

105

105

European Pharmaceutical Review

JANUARY 31, 2023

It is the “… first and only targeted treatment option clinically proven to reduce both oesophageal inflammation and damage,” explained Dr Naimish Patel, Head of Global Development, Immunology and Inflammation at Sanofi. All patients had previously not responded to proton pump inhibitors.

93

93

FDA Law Blog: Biosimilars

AUGUST 28, 2023

Lenz, Principal Medical Device Regulation Expert — Following up on our first post discussing Digital Health Technologies (DHTs) ( here ), this post will focus on development and qualification of DHTs for use in clinical trials for drug development. While desirable for patients, validation on multiple platforms can lead to challenges.

Drug Development 59

Drug Development 59

Board Vitals - Pharmacist

NOVEMBER 6, 2023

These resources cover a range of topics to ensure you are prepared for exam day. Kaufman: Designed for medical students and residents, this guide offers a concise yet comprehensive overview of key psychiatry topics. Kenny: This review manual provides a concise yet comprehensive overview of psychiatry topics. Toy and Debra L.

Compounding 52

Compounding Communication Hospitals 52

Pharmaceutical Technology

DECEMBER 18, 2022

The EMA positive opinion is based on clinical findings of mRNA.1273.214, Moderna’s paediatric application is based on clinical trial booster findings for Spikevax, the company’s original vaccine. Additionally, the application included findings from a Phase II/III clinical trial of mRNA-1273.214. 5), mRNA-1273.

Vaccines 121

Vaccines Communication 121

pharmaphorum

JANUARY 27, 2023

Late last year, pharmaphorum caught up with Dr Karen Mullen, chief medical officer and VP of clinical & medical affairs at global drug development consultancy Boyds. Clinical trials design and patient input The definition of patient centricity, in fact, and its benefits are now – finally – being defined by patients themselves. “We

Vaccines 111

Vaccines Pharmaceutical Companies Pharmaceutical Companies Documentation 111

Pharmaceutical Technology

JULY 12, 2022

The Roflumilast cream is a once-a-day topical formulation of the selective phosphodiesterase type 4 (PDE4) inhibitor, roflumilast. The NDS submission by Arcutis is based on positive findings from the company’s pivotal Phase III programme and two long-term open-label clinical trials. versus a vehicle rate of 6.1%

Labelling 64

Labelling Immunity Immunization 64

PharmaShots

MARCH 30, 2023

Equity investment into Galimedix supports Galimedix's pipeline development TOI gets an exclusive right to develop & commercialize Galimedix’s GAL-101 for topical & oral treatment of dry AMD, glaucoma & other ophthalmic indications in the EU, the Americas, the Middle East & Africa.

40

40

Pharmaceutical Technology

OCTOBER 25, 2022

Additionally, Astellas will obtain an exclusive option for licencing two clinical-stage programmes of Taysha, namely TSHA-102 and TSHA-120, for Rett syndrome and GAN, respectively. Topic sponsors are not involved in the creation of editorial content. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

105

105

Pharmaceutical Technology

JUNE 13, 2023

Amongst it was AGTC’s lead clinical candidate, AFTC-501, an adeno-associated virus (AAV) gene therapy for XLRP. The asset, now transferred to Beacon Therapeutics, is currently in Phase II clinical trials. Beacon Therapeutics says it expects 12-month data from the SKYLINE trial in H2 2023.

98

98

European Pharmaceutical Review

JUNE 26, 2023

Real-world evidence (RWE) from these studies can complement evidence from other sources including clinical trials. Additionally, studies to inform the design and feasibility of clinical trials and clinical management were appraised too. These included safety, drug utilisation and disease epidemiology studies.

Medical Records 84

Medical Records Clinic Management 84